Highly purified CD34-positive cells reconstitute hematopoiesis

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2224-2233

  Civin, C I ^a   Trischmann, T ^a   Kadan, N S ^a   Davis, J ^a   Noga, S ^a   Cohen, K ^a   Duffy, B ^a   Groenewegen, I ^a   Wiley, J ^a   Law, P ^a   Hardwick, A ^a   Oldham, F ^a   Gee, A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL SELECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL; HUMAN; MALE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 9444269823     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2224     Document Type: Article

References (44)

1. Bonilla MA, Cheung NV: Clinical progress in neuroblastoma. Cancer Invest 12:644-653, 1994
2. Graham-Pole J, Casper J, Elfenbein G: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:152-158, 1991
3. Phillip T, Zucker JM, Bernard JL: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1037-1044, 1991
4. Hartmann O, Benhamau E, Beaujean F, et al: High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A phase II study. J Clin Oncol 4:1804-1810, 1986
5. Graham ML, Yeager AM, Leventhal BG, et al: Treatment of recurrent refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue. J Clin Oncol 10:1857-1864, 1992
6. Alien JC, Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55:749-756, 1981
7. Seeger R, Reynolds C: Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 38:393-424, 1991
8. Wiley JM, Leventhal BG, Fresia A, et al: High dose carboplatin (CBDCA). etoposide (VP-16) and cyclophosphamide (CY) with autologous bone marrow rescue (ABMR) in children and young adults with solid tumors: Results of a phase I study. Proc Am Soc Clin Oncol 12:419a, 1993 (abstr)
9. Wiley J, Fresia A, Strauss L, et al: High dose carboplatin (CBDCA), etoposide (VP-16) and cyclophosphamide (CY) with autologous bone marrow rescue (ABMR) in children and young adults with refractory solid or brain tumors. Proc Am Soc Clin Oncol 11:374a, 1993 (abstr)
10. Wiley JM, Strauss LC, Fresia A, et al: High dose chemotherapy and autologous bone marrow rescue in poor risk sarcoma patients. A report of a pilot study in pediatric sarcomas. Proceedings of the Sixth International Symposium on Autologous Bone Marrow Transplantation, Arlington, VA, 1993, pp 199-204
11. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994
12. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma [see comments]. N Engl J Med 325:1525-1533, 1991
13. Rowley SD, Zuehlsdorf M, Braine HG, et al: CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 70:271-275, 1987
14. Gribben JG, Neuberg D, Freedman AS, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 transloca- tion is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457, 1993
15. Krause D, Ito T, Fackler M, et al: Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. Blood 84:691-701, 1994
16. Silvestri F, Banavali S, Baccarani M, et al: The CD34 hemopoietic progenitor cell associated antigen: Biology and clinical applications. Haematologica 77:265-272, 1992
17. + marrow cells in patients with breast cancer or neuroblastoma. Blood 77:1717-1722, 1991
18. + hematopoietic progenitor cells into breast cancer patients following high-dose chemotherapy. J Clin Oncol 12:28-36, 1994
19. Brugger W, Heimbeld S, Berenson R, et al: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333:283-287, 1995
20. Krause DS, Fackler MJ, Civin CI, et al: CD34: Structure, biology, and clinical utility. Blood 87:1-13, 1996
21. Tsay Y-G, Jones R, Calenoff E, et al: A preoperative chymopapain sensitivity test for chemonucleolysis candidates. Spine 9:764-768, 1984
22. Hardwick A, Law P, Mansour V, et al: Development of a large-scale inimunomagnetic separation system for harvesting CD34-positive cells from bone marrow, in Gross S, Gee AP, Worthington-White DA (eds): Advances in Bone Marrow Purging and Processing. New York, NY, Wiley-Liss, 1992. pp 583-589
23. + cells from human bone marrow, cord blood, and mobilized peripheral blood. J Hematother 2:333-338, 1993
24. + cells in bone marrow by flow cytometry. J Hematother 2:305-313, 1993
25. Civin CI, Strauss LC, Fackler MJ, et al: Positive stem cell selection: Basic science, in Gross S, Gee A, Worhtington-White D (eds): Bone Marrow Purging and Processing. New York, NY, Liss, 1990, pp 387-402
26. Strauss L, Trischmann T, Rowley S, et al: Selection of normal human hematopoietic stem cells for bone marrow transplantation using immunomagnetic microspheres and CD34 antibody. Am J Pediatr Oncol 13:217-221, 1991
27. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
28. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
29. Brodeur GM, Fong CT: Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 41:153-174, 1989
30. Canetta R, Franks C, Smaldone L, et al: Clinical status of carboplatin. Oncology 1:61-70, 1987
31. Legha SS, Dimery IW: High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity. J Clin Oncol 3:1373-1378, 1985
32. Berman M, Feldrnan S, Alter M, et al: Acute transverse myelitis: incidence and etiologic considerations. Neurology 31:966-971, 1981
33. Eguro H: Transverse myelitis following chemonucleolysis. J Bone Joint Surg 65:1328-1329, 1983
34. Hirst E, Robertson TI: The syndrome of thymoma and erythroblastopenic anemia. Medicine (Baltimore) 46:225-264, 1967
35. Ladenstein R, Lasset C, Hartmann O, et al: Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: Report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 14:37-46, 1994
36. Moss TJ, Cairo M, Santana VM: Clonogenicity of circulating neuroblastoma cells: Implications regarding peripheral blood stem cell transplantation. Blood 83:3085-3089, 1994
37. Moss TJ, Xu ZJ, Mansour V: Quantitation of tumor cell removal from bone marrow: A preclinical model. J Hematother 1:65-73, 1992
38. Ross AM, Cooper BW, Lazarus HM: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605-2610, 1993
39. + progenitor/stem cells for transplantation. Hematol Rev 8:15-25, 1994
40. Champagne MA, Amin S, Civin CI: CD34 Positive selection (PS) is effective for cancer purging and purging efficacy (PE) can be calculated from clinically measureable parameters. Blood 80:232a, 1992 (suppl 1, abstr)
41. Matthay KK, Seeger RC, Reynolds CP, et al: Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group. J Clin Oncol 12:2382-2389, 1994
42. + blood stem cells for autologous rescue in children with poor prognosis solid tumors. Blood 86:403a. 1995 (suppl 1, abstr)
43. + cells. Int J Cell Cloning 10:108-110, 1992
44. + cells. Leukemia 6:845-852, 1992